Needle-free tech enters Japanese growth hormone market:
This article was originally published in Clinica
Executive Summary
Antares Pharma has reported that its needle-free injection technology has become the first such product to enter the Japanese human growth hormone market. The firm's Japanese licensee, JCR Pharmaceuticals Co, of Ashiya, this month launched the Twin-Jector EZ II, a product that combines Antares' Vision needle-free technology with JCR's growth hormone. Japan represents the highest value market for human growth hormone products, said Antares CEO Roger Harrison. Antares' needle-free technology was launched in the European human growth hormone market in 1997. "For the year ended December 31 2003, the majority of our reported product revenues was derived from this sector of our business," Mr Harrison said. Under the deal with JCR, Antares will receive manufacturing margins on sales of devices as well as royalties on the end sales of human growth hormone used with the needle-free technology.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.